	Application No.	Applicant(s)
Notice of Allowability		
	10/552,492 Examiner	BUSCH-PETERSEN ET AL. Art Unit
	Michael P. Barker	1626
The MAILING DATE of this communication apperation apperation allowable, PROSECUTION ON THE MERITS IS therewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	olication. If not included will be mailed in due course. THIS
1. This communication is responsive to <u>10/7/2005</u> .		•
2. The allowed claim(s) is/are 1,2,4 and 5.		
 3. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 	been received.	
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. ☑ Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application
2. Notice of Praftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	
<u> </u>	Paper No./Mail Dat	te
 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 10/7/2005 	7. 🛛 Examiner's Amendr	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. 🛛 Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.	

Claims 1-7 are pending. Claims 3, 6, and 7 are canceled and Claim 4 is amended via Examiner's Amendment, *infra*. Claims 1, 2, 4, and 5 are in condition for allowance.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on October 7, 2005 was correctly filed. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the IDS was considered by the Examiner. Please refer to Applicant's copy of PTO-1449, submitted herewith.

Examiner's Amendment

An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Soma Simon on February 27, 2007.

The application has been amended as follows:

Claim 3: Cancel.

Claim 4: Replace entire text with the following text:

"4. A method of treating chronic obstructive pulmonary disorder comprising administering an effective amound of a compound according to claim 1 to a patient in need thereof."

Art Unit: 1626

Claim 5: After the words, "pharmaceutical formulation comprising", delete the words, "an active", and insert, "a compound".

Claim 6: Cancel.

Claim 7: Cancel.

Reasons for Allowance

Applicant's invention is drawn to compounds, pharmaceutical formulations, and a method of treatment using compounds of Formula (I), depicted in **Claim 1**. There is no prior art which anticipates or renders Applicant's instantly claimed compounds and compositions obvious.

The closest prior art is U.S. Patent No. 6,060,473, issued May 9, 2000. The '473 patent discloses compounds and compositions which contain an azabicycloheptane core and are capable of inhibiting cholinergic activity. Despite the similar core and use, the compounds disclosed in the '473 Patent do not meet each limitation of the instant compounds. Most notably, the instant compounds teach two azabicycloheptane-cored compounds with a specificity for M3 muscarinic acetylcholine receptor antagonism.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael P. Barker whose telephone number is (571) 272-4341. The examiner can normally be reached on Monday-Friday 8:00 AM- 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Joseph K.

Application/Control Number: 10/552,492 Page 4

Art Unit: 1626

McKane, can be reached at (571) 272-0699. The unofficial fax phone for this group are (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is viable through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael P. Barker

Patent Examiner, AU 1626

Joseph M[⊾]Kane

Supervisory Patent Examiner, AU 1626